A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects

OBJECTIVE: SB2, a biosimilar to infliximab reference product (INF), has an identical amino acid sequence and similar physicochemical functional properties to its reference product. The primary objective of this study is to demonstrate pharmacokinetic (PK) bioequivalence between SB2 and EU-sourced IN...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Donghoon, Kim, Youngdoe, Kim, Yoo Seok, Körnicke, Thomas, Fuhr, Rainard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684585/
https://www.ncbi.nlm.nih.gov/pubmed/26577771
http://dx.doi.org/10.1007/s40259-015-0150-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684585/
https://www.ncbi.nlm.nih.gov/pubmed/26577771
http://dx.doi.org/10.1007/s40259-015-0150-5

Ejemplares similares